WO2000033825A3 - Compositions and methods for amelioration of human female sexual dysfunction - Google Patents

Compositions and methods for amelioration of human female sexual dysfunction Download PDF

Info

Publication number
WO2000033825A3
WO2000033825A3 PCT/US1999/029471 US9929471W WO0033825A3 WO 2000033825 A3 WO2000033825 A3 WO 2000033825A3 US 9929471 W US9929471 W US 9929471W WO 0033825 A3 WO0033825 A3 WO 0033825A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
female sexual
sexual dysfunction
amelioration
compositions
Prior art date
Application number
PCT/US1999/029471
Other languages
French (fr)
Other versions
WO2000033825A2 (en
Inventor
James L Yeager
Nadir Buyuktimkin
Servet Buyuktimkin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU23586/00A priority Critical patent/AU760112B2/en
Priority to AT99967277T priority patent/ATE265849T1/en
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Priority to CA002354695A priority patent/CA2354695C/en
Priority to HU0200067A priority patent/HU229083B1/en
Priority to DK99967277T priority patent/DK1137409T3/en
Priority to BR9916076-5A priority patent/BR9916076A/en
Priority to IL14366199A priority patent/IL143661A0/en
Priority to EP99967277A priority patent/EP1137409B1/en
Priority to DE69917066T priority patent/DE69917066T2/en
Priority to JP2000586318A priority patent/JP4616480B2/en
Priority to MXPA01005748A priority patent/MXPA01005748A/en
Publication of WO2000033825A2 publication Critical patent/WO2000033825A2/en
Publication of WO2000033825A3 publication Critical patent/WO2000033825A3/en
Priority to IL143661A priority patent/IL143661A/en
Priority to HK02100568.0A priority patent/HK1039067B/en
Priority to US10/188,554 priority patent/US6825234B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a composition suitable for topical application comprising: an effective amount of a prostaglandin, a polymer thickener, a lipophilic component, and a buffer system. In another embodiment, the invention provides a composition suitable for topical application comprising: an effective amount of a vasoactive agent, a polymer thickener, a lipophilic component, and a buffer system. The invention also provides methods of ameliorating female sexual dysfunction. Also provided are methods of increasing female sexual arousal and methods of enhancing female sexual response.
PCT/US1999/029471 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction WO2000033825A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE69917066T DE69917066T2 (en) 1998-12-10 1999-12-10 COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL FUNCTIONAL DISORDERS IN WOMEN
EP99967277A EP1137409B1 (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction
CA002354695A CA2354695C (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction
AT99967277T ATE265849T1 (en) 1998-12-10 1999-12-10 COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL FUNCTIONAL DISORDERS IN WOMEN
DK99967277T DK1137409T3 (en) 1998-12-10 1999-12-10 Preparations and Methods for Relieving Human Female Sexual Dysfunction
BR9916076-5A BR9916076A (en) 1998-12-10 1999-12-10 Composition suitable for topical application, use of a topical composition methods to improve female sex drive disorder, and to enhance female sex drive, and female sexual response, article of manufacture
JP2000586318A JP4616480B2 (en) 1998-12-10 1999-12-10 Compositions and methods for recovery of sexual dysfunction in human women
AU23586/00A AU760112B2 (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction
HU0200067A HU229083B1 (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction
IL14366199A IL143661A0 (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction
MXPA01005748A MXPA01005748A (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction.
IL143661A IL143661A (en) 1998-12-10 2001-06-10 Compositions for amelioration of human female sexual dysfunction
HK02100568.0A HK1039067B (en) 1998-12-10 2002-01-24 Compositions and methods for amelioration of human female sexual dysfunction
US10/188,554 US6825234B2 (en) 1998-12-10 2002-07-02 Compositions and methods for amelioration of human female sexual dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/208,965 1998-12-10
US09/208,965 US6486207B2 (en) 1998-12-10 1998-12-10 Compositions and methods for amelioration of human female sexual dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/208,965 Continuation-In-Part US6486207B2 (en) 1998-12-10 1998-12-10 Compositions and methods for amelioration of human female sexual dysfunction

Publications (2)

Publication Number Publication Date
WO2000033825A2 WO2000033825A2 (en) 2000-06-15
WO2000033825A3 true WO2000033825A3 (en) 2000-11-16

Family

ID=22776778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029471 WO2000033825A2 (en) 1998-12-10 1999-12-10 Compositions and methods for amelioration of human female sexual dysfunction

Country Status (19)

Country Link
US (1) US6486207B2 (en)
EP (1) EP1137409B1 (en)
JP (1) JP4616480B2 (en)
KR (1) KR100660239B1 (en)
CN (1) CN1173700C (en)
AT (1) ATE265849T1 (en)
AU (1) AU760112B2 (en)
BR (1) BR9916076A (en)
CA (1) CA2354695C (en)
DE (1) DE69917066T2 (en)
DK (1) DK1137409T3 (en)
ES (1) ES2217878T3 (en)
HK (1) HK1039067B (en)
HU (1) HU229083B1 (en)
IL (2) IL143661A0 (en)
MX (1) MXPA01005748A (en)
PT (1) PT1137409E (en)
WO (1) WO2000033825A2 (en)
ZA (1) ZA200104697B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8874215B2 (en) 2008-10-10 2014-10-28 Peter Forsell System, an apparatus, and a method for treating a sexual dysfunctional female patient
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8961448B2 (en) 2008-01-28 2015-02-24 Peter Forsell Implantable drainage device
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072907B2 (en) 2008-10-10 2015-07-07 Peter Forsell Heart help device, system, and method
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9526649B2 (en) 2008-10-10 2016-12-27 Peter Forsell Method and instrument for treating obesity
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (en) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Use of a prostaglandin-based composition for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
EP1220666A2 (en) * 1999-04-06 2002-07-10 Zonagen, Inc. Methods for modulating the human sexual response
US20050244520A1 (en) * 1999-07-01 2005-11-03 40J's Llc Topical menthol, or a related cooling compound, to induce lubrication
US6702733B1 (en) * 1999-07-01 2004-03-09 40 J's Llc Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds
US20010029268A1 (en) * 1999-07-01 2001-10-11 Thompson Ronald J. Clitoral sensitizing arrangement using compound of menthol and L-arginine
US6464628B1 (en) * 1999-08-12 2002-10-15 Obtech Medical Ag Mechanical anal incontinence
IL139456A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
WO2001047434A2 (en) * 2000-02-10 2001-07-05 Potencia Medical Ag Mechanical impotence treatment apparatus
US7442165B2 (en) * 2000-02-14 2008-10-28 Obtech Medical Ag Penile prosthesis
US6762202B2 (en) * 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB2372213B (en) * 2000-11-17 2003-07-16 Icebella Enterpises Ltd Applicator and stimulator device
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US6673841B2 (en) * 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
GB0130704D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd New use
IL162154A0 (en) * 2002-02-15 2005-11-20 Nexmed Holdings Inc Prostagandin composition for the treatment of erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2004224413A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
CN1774237A (en) * 2003-03-21 2006-05-17 尼克美制药控股有限公司 Angiogenesis promotion by prostaglandin compositions and methods
KR20050119187A (en) * 2003-04-02 2005-12-20 넥스메드 홀딩스 인코포레이티드 Prostaglandin compositions and their use for the treatment of vasospasm
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
JP5068543B2 (en) * 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト Diagnostic markers for cancer
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
US20050276865A1 (en) * 2004-05-20 2005-12-15 Servet Buyuktimkin Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20070059250A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
ES2383650T3 (en) 2005-11-02 2012-06-25 Injectica Ag Perfusion device with extensible and retractable needle, susceptible to implantation
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
HUE055695T2 (en) 2007-10-11 2021-12-28 Implantica Patent Ltd Apparatus for controlling flow in a bodily organ
WO2009048382A1 (en) * 2007-10-11 2009-04-16 Milux Holding Sa Apparatus for treating female sexual dysfunction
EP2214775B1 (en) * 2007-10-11 2021-07-21 Implantica Patent Ltd. A system for treating a sexual dysfunctional female patient
EP2214570B1 (en) 2007-10-11 2021-08-04 Implantica Patent Ltd. Apparatus and system for the treatment of female sexual dysfunction
US8696543B2 (en) * 2007-10-11 2014-04-15 Kirk Promotion Ltd. Method for controlling flow of intestinal contents in a patient's intestines
US8795153B2 (en) 2007-10-11 2014-08-05 Peter Forsell Method for treating female sexual dysfunction
EP2211768B1 (en) * 2007-10-11 2021-03-24 Implantica Patent Ltd. Apparatus for controlling flow in a bodily organ
US8992409B2 (en) * 2007-10-11 2015-03-31 Peter Forsell Method for controlling flow in a bodily organ
WO2010042044A1 (en) 2008-10-10 2010-04-15 Milux Holding S.A. A system, an apparatus, and a method for treating a sexual dysfunctional female patient
EP2349096B1 (en) 2008-10-10 2021-01-27 MedicalTree Patent Ltd. An improved artificial valve
EP2349170B1 (en) 2008-10-10 2023-09-27 Implantica Patent Ltd. Apparatus for the treatment of female sexual dysfunction
WO2010042032A1 (en) 2008-10-10 2010-04-15 Milux Holding S.A. Fastening means for implantable medcial control assembly
US20110196484A1 (en) 2008-10-10 2011-08-11 Milux Holding Sa Heart help method
EP2349399B1 (en) 2008-10-10 2014-09-24 Kirk Promotion LTD. Stimulation of sexually responsive tissue of the vulva
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
PT2442650E (en) 2009-06-12 2015-12-18 Cynapsus Therapeutics Inc Sublingual apomorphine
US10952836B2 (en) 2009-07-17 2021-03-23 Peter Forsell Vaginal operation method for the treatment of urinary incontinence in women
US9949812B2 (en) 2009-07-17 2018-04-24 Peter Forsell Vaginal operation method for the treatment of anal incontinence in women
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
DK2651357T3 (en) 2010-12-16 2020-06-02 Sunovion Pharmaceuticals Inc Sublingual film
RU2633236C2 (en) 2011-04-07 2017-10-11 Нексмед Холдингс, Инк. Methods and compositions for raynaud disease treatment
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
WO2015172102A1 (en) * 2014-05-09 2015-11-12 Nexmed Holdings, Inc. Treating female sexual arousal disorder and related symptoms
JP7211706B2 (en) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド Method for treating Parkinson's disease by administering apomorphine to oral mucosa
US10130578B2 (en) * 2015-07-23 2018-11-20 Johnson & Johnson Consumer Inc. Topical delivery of skin compositions having low pH
MX2020012139A (en) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Compositions and methods for treating rosacea and acne.
IL258017B (en) * 2018-03-11 2019-10-31 Aquafit Intimate Ltd Intravaginal device and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004120A2 (en) * 1992-08-21 1994-03-03 Roberto Dias Nahoum Cesar Methods of treating sexual dysfunction in animals with and h agonist
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3852465A (en) 1972-09-21 1974-12-03 Upjohn Co Abortion by myometrial administration of prostaglandins
US4005221A (en) 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4217360A (en) 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4043339A (en) 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
JPS52156913A (en) 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
AU519132B2 (en) 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
JPS5573676A (en) 1978-11-30 1980-06-03 Ono Pharmaceut Co Ltd Simulated compound of prostaglandin i2 and its preparation
JPS5589297A (en) 1978-12-28 1980-07-05 Kureha Chem Ind Co Ltd Prostaglandin derivative, its preparation and its drug
SE431821B (en) 1979-01-29 1984-03-05 Perstorp Ab STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
USRE30439E (en) 1979-03-12 1980-11-25 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4317447A (en) 1979-07-19 1982-03-02 Ortho Pharmaceutical Corporation Drug delivery system
US4289785A (en) 1980-08-06 1981-09-15 The Upjohn Company Method and compositions involving prostaglandins
ZA831186B (en) 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4515810A (en) 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
JPS61249934A (en) * 1985-04-27 1986-11-07 Nitto Electric Ind Co Ltd Composition for application to cuticle
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US4771004A (en) 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
EP0266968A3 (en) 1986-11-03 1988-08-24 Gérard G. Cohen Gelled ointment of vasodilating agent
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
JPS63135333A (en) 1986-11-26 1988-06-07 Nitto Electric Ind Co Ltd Plaster containing prostaglandins
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
IT1221826B (en) 1988-06-08 1990-07-12 Medico Harvey Srl Centro PREPARED FOR TOPICAL USE FOR THE THERAPEUTIC TREATMENT OF IMPOTENTIA COEUNDI
SE463851B (en) 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
JP2910857B2 (en) 1989-04-04 1999-06-23 ニチバン株式会社 Prostaglandin E1 transdermal preparation
JP2926749B2 (en) * 1989-04-25 1999-07-28 吉富製薬株式会社 Prostaglandin-containing liquid composition
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
JPH0737389B2 (en) * 1989-08-29 1995-04-26 久光製薬株式会社 Ointment containing prostaglandin E1
KR0169950B1 (en) 1990-04-25 1999-01-15 에드워드 엘. 멘델 Dosage and inserter for treatment of erectile dysfunction
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
WO1993000894A1 (en) 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
AU658681B2 (en) 1991-10-23 1995-04-27 Block Drug Company Inc., The Penetration enhancement of topically applied formulations
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
AU5358896A (en) 1995-03-14 1996-10-02 Vivus, Inc. Method and kit for preventing erectile dysfunction
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
DE69718037T2 (en) * 1996-10-24 2003-07-10 Alza Corp PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES, DEVICES AND METHODS FOR THE PRODUCTION THEREOF
US20020004529A1 (en) 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6046240A (en) 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004120A2 (en) * 1992-08-21 1994-03-03 Roberto Dias Nahoum Cesar Methods of treating sexual dysfunction in animals with and h agonist
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOLDVARI M., ET AL.: "Transcutaneous delivery of prostaglandin E1: In vitro and laser doppler flowmetry study", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 6, June 1998 (1998-06-01), pages 721 - 725, XP000917917 *
GOLDSTEIN I., ET AL.: "Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndromes", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, vol. 10, no. suppl. 2, 1998, pages s84 - s90, XP000891788 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8961448B2 (en) 2008-01-28 2015-02-24 Peter Forsell Implantable drainage device
US8874215B2 (en) 2008-10-10 2014-10-28 Peter Forsell System, an apparatus, and a method for treating a sexual dysfunctional female patient
US9370656B2 (en) 2008-10-10 2016-06-21 Peter Forsell System, an apparatus, and a method for treating a sexual dysfunctional female patient
US9526649B2 (en) 2008-10-10 2016-12-27 Peter Forsell Method and instrument for treating obesity
US9072907B2 (en) 2008-10-10 2015-07-07 Peter Forsell Heart help device, system, and method
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions

Also Published As

Publication number Publication date
IL143661A (en) 2006-06-11
EP1137409B1 (en) 2004-05-06
IL143661A0 (en) 2002-04-21
AU760112B2 (en) 2003-05-08
ZA200104697B (en) 2002-08-28
KR100660239B1 (en) 2006-12-20
US20020028846A1 (en) 2002-03-07
ATE265849T1 (en) 2004-05-15
ES2217878T3 (en) 2004-11-01
DE69917066T2 (en) 2005-04-28
HU229083B1 (en) 2013-07-29
HUP0200067A2 (en) 2002-06-29
KR20020068257A (en) 2002-08-27
DK1137409T3 (en) 2004-08-02
PT1137409E (en) 2004-08-31
JP4616480B2 (en) 2011-01-19
DE69917066D1 (en) 2004-06-09
HK1039067A1 (en) 2002-04-12
BR9916076A (en) 2001-09-04
CA2354695C (en) 2005-01-25
US6486207B2 (en) 2002-11-26
CA2354695A1 (en) 2000-06-15
WO2000033825A2 (en) 2000-06-15
MXPA01005748A (en) 2003-07-14
CN1330543A (en) 2002-01-09
CN1173700C (en) 2004-11-03
HUP0200067A3 (en) 2005-03-29
HK1039067B (en) 2004-10-08
AU2358600A (en) 2000-06-26
EP1137409A2 (en) 2001-10-04
JP2002531494A (en) 2002-09-24

Similar Documents

Publication Publication Date Title
WO2000033825A3 (en) Compositions and methods for amelioration of human female sexual dysfunction
WO2004004689A8 (en) Compositions and methods for amelioration of human female sexual dysfunction
EP1028720A4 (en) Methods, compositions, and kits for enhancing female sexual desire and responsiveness
WO1999058555A3 (en) Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
AU2001245401A1 (en) Hydrazones and analogs as cholesterol lowering agents
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
WO1998042274A3 (en) Implant body and rotatory body
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
AU2002253018A1 (en) Skin composition for reducing skin oils and grease
WO2003050137A3 (en) Toll-like receptor 4 mutations
AU1293600A (en) Oil from momordica charantia l., its method of preparation and uses
CA2343116A1 (en) Methods and compositions for increasing intestinal absorption of fats
AU2001269730A1 (en) Low carbohydrate compositions, kits thereof, and methods of use
CA2354770A1 (en) Compositions with enhanced photoprotective effect and method for using same
WO2001085188A3 (en) Use of echinacea as a hematinic agent
AU2002216704A1 (en) Compositions having comfrey and methods for reducing retinoid-induced skin irritation
WO2001076358A3 (en) Horse-rug
AU2002361994A1 (en) Agent for use in sandy soils and method for improving sandy soils by using this agent
GB2325855A8 (en) Preperation for topical application to the male sexual organ comprising at least one vasodilator & an aloe extract as active ingredients in an aq cream or gel
AU2001227738A1 (en) Piston pin retainer and method of using the same
WO2000002579A3 (en) Component b as angiogenic agent in combination with human growth factors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814316.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005748

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 143661

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2000 586318

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007273

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 23586/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999967277

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967277

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2354695

Country of ref document: CA

Ref document number: 2354695

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017007273

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 23586/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999967277

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017007273

Country of ref document: KR